Core Insights - NeOnc Technologies Holdings, Inc. is hosting an investor conference call on November 12, 2025, to discuss updates on its clinical trials and therapeutic developments [1][2]. Company Overview - NeOnc is a clinical-stage biopharmaceutical company focused on developing brain-penetrant therapeutics for malignant brain tumors and CNS disorders [1][3]. - The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates with patent protections extending to 2038 [3]. - NEO100 and NEO212 therapeutics are currently in Phase II human clinical trials and are advancing under FDA Fast-Track and IND status [3]. Clinical Trial Updates - The conference call will present data from the ongoing Phase 1/2a NEO100-1 clinical trial and compassionate use program, focusing on intranasal delivery of NEO100 in patients with recurrent high-grade malignant glioma [2][3]. - The discussion will include MRI-based radiographic response data, progression-free survival (PFS), and overall survival (OS) trends observed to date, providing insights into long-term clinical outcomes for patients treated with NEO100 [3]. Key Participants - Featured participants in the conference call include members of the NTHI management team and independent members of the Scientific Advisory Board [2][6]. - Notable participants include Dr. Henry S. Friedman and Dr. Alexander Miller, both recognized experts in neuro-oncology [6]. Conference Call Details - The investor conference call is scheduled for November 12, 2025, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time [1][6]. - A live webcast of the call will be available on the company's investor relations website [6].

Core Insights - NeOnc Technologies Holdings, Inc. has appointed Amir Heshmatpour as Chief Executive Officer, effective immediately, while Dr. Thomas Chen transitions to focus on his roles as Chief Medical Officer and Chief Scientific Officer [1][2][3] - Heshmatpour has a strong background in corporate strategy and business development, which is expected to drive NeOnc's lead candidates toward commercialization [3][4] - The company is advancing its NEO™ platform, which is protected by over 179 patents, and aims to transform care for patients with CNS cancers [4][6] Company Leadership Transition - Amir Heshmatpour, previously President, will now serve as CEO and continue as Executive Chairman [1][4] - Dr. Thomas Chen, the founder, will concentrate on clinical trials and scientific strategy, ensuring leadership in innovative developments [2][3] Strategic Achievements - Under Heshmatpour's leadership, NeOnc secured a $50 million strategic partnership with Quazar Investment and established a UAE-based subsidiary, NuroMENA [3] - The company has expanded its Scientific Advisory Board with renowned neuro-oncologists from Duke and NYU Langone Health [3] Product Development and Clinical Trials - NeOnc's NEO100™ and NEO212™ therapeutics are currently in Phase II human clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [6] - The company focuses on overcoming the blood-brain barrier with its proprietary chemotherapy agents, which have shown positive effects in laboratory tests and clinical trials [6]

Core Insights - NeOnc Technologies Holdings, Inc. has appointed His Highness Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman of its Middle East subsidiary, NuroMENA Holdings Ltd., marking a significant development in the company's strategy to innovate in global healthcare [1][3] - The collaboration aims to advance biotechnology efforts focused on breakthrough treatments for brain cancer and other central nervous system malignancies, leveraging the resources of one of the world's largest sovereign wealth funds [2][3] Company Overview - NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company dedicated to developing therapeutics for central nervous system conditions, particularly targeting the blood-brain barrier [5] - The company's proprietary NEO™ drug development platform has produced novel drug candidates, with patent protections extending to 2038, and its therapeutics NEO100™ and NEO212™ are currently in Phase II clinical trials under FDA Fast-Track and Investigational New Drug status [5] Strategic Importance - The involvement of His Highness Sheikh Nahyan bin Zayed Al Nahyan is expected to fundamentally change the trajectory of NeOnc Technologies, providing new hope for patients suffering from brain cancer globally [3] - This strategic alliance highlights the UAE's commitment to addressing critical healthcare challenges and positions the country at the forefront of medical innovation [3][4]

Core Insights - NeOnc Technologies Holdings, Inc. has appointed Dr. Henry S. Friedman to its scientific advisory board, enhancing its expertise in neuro-oncology [1][2][4] - Dr. Friedman is a prominent figure in the field, with over 500 peer-reviewed publications and extensive experience in developing therapies for CNS cancers [4] - The company is preparing to publish data from its clinical programs NEO100 and NEO212, which are in Phase II trials and have received FDA Fast-Track and IND status [3][5] Company Overview - NeOnc Technologies is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system cancers, particularly addressing challenges related to the blood-brain barrier [5] - The company's NEO™ drug development platform has produced a portfolio of novel drug candidates with patent protections extending to 2038 [5] - NEO100 and NEO212 are proprietary chemotherapy agents that have shown positive effects in laboratory tests and clinical trials for malignant gliomas [5] Leadership and Strategy - The appointment of Dr. Friedman is expected to strengthen the company's pipeline and enhance stakeholder confidence as it advances its clinical programs [2][3] - The company aims to change the future for patients with glioblastoma and other brain cancers through innovative therapies and collaborative research efforts [3][4]